Kamal Mostafa

CEO, Magellan Rx ManagementMAGELLAN HEALTH INC (MGLN) · full profile →Form 4 · filed Jan 4, 2022
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
7
1 non-derivative · 6 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 4, 2022Disposed to issuer(D)6K0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 4, 2022Disposed to issuer(D)27K0
Jan 4, 2022Disposed to issuer(D)12K0
Jan 4, 2022Disposed to issuer(D)25K0
Jan 4, 2022Disposed to issuer(D)16K0
Jan 4, 2022Disposed to issuer(D)11K0
Jan 4, 2022Disposed to issuer(D)25K0

Transaction Codes

D
Disposition to the issuer

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-22-000981) within minutes of acceptance. Every field above traces to the original document. Verify it directly: